Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Larisa Prpić-Massari
 -- 4329 2022-07-14 10:51:02 |
2 format
Jason Zhu
 Meta information modification 4329 2022-07-15 07:42:02 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Hlača, N.;  Žagar, T.;  Kaštelan, M.;  Brajac, I.;  Prpić-Massari, L. Immunopathogenesis of Vitiligo. Encyclopedia. Available online: https://encyclopedia.pub/entry/25139 (accessed on 28 September 2024).
Hlača N,  Žagar T,  Kaštelan M,  Brajac I,  Prpić-Massari L. Immunopathogenesis of Vitiligo. Encyclopedia. Available at: https://encyclopedia.pub/entry/25139. Accessed September 28, 2024.
Hlača, Nika, Tina Žagar, Marija Kaštelan, Ines Brajac, Larisa Prpić-Massari. "Immunopathogenesis of Vitiligo" Encyclopedia, https://encyclopedia.pub/entry/25139 (accessed September 28, 2024).
Hlača, N.,  Žagar, T.,  Kaštelan, M.,  Brajac, I., & Prpić-Massari, L. (2022, July 14). Immunopathogenesis of Vitiligo. In Encyclopedia. https://encyclopedia.pub/entry/25139
Hlača, Nika, et al. "Immunopathogenesis of Vitiligo." Encyclopedia. Web. 14 July, 2022.
Immunopathogenesis of Vitiligo
Edit
This entry is adapted from the peer-reviewed paper 10.3390/biomedicines10071639

Vitiligo is an acquired immune-mediated disorder of pigmentation clinically characterized by well-defined depigmented or chalk-white macules and patches on the skin. The prevalence of vitiligo varies by geographical area, affecting 0.5% to 2% of the population. The disease imposes a significant psychological burden due to its major impact on patients’ social and emotional aspects of life. Given its autoimmune background, vitiligo is frequently associated with other autoimmune diseases or immune-mediated diseases. Vitiligo is a multifaceted disorder that involves both genetic predisposition and environmental triggers. In recent years, major predisposing genetic loci for the development of vitiligo have been discovered. Oxidative-stress-mediated activation of innate immunity cells such as dendritic cells, natural killer, and ILC-1 cells is thought to be a key event in the early onset of vitiligo. Innate immunity cells serve as a bridge to adaptive immunity cells including T helper 1 cells, cytotoxic T cells and resident memory T cells. IFN-γ is the primary cytokine mediator that activates the JAK/STAT pathway, causing keratinocytes to produce the key chemokines CXCL9 and CXCL10. Complex interactions between immune and non-immune cells finally result in apoptosis of melanocytes.

autoimmune diseases dendritic cells keratinocytes melanocytes vitiligo

1. Introduction

Similar to other immune-mediated skin diseases, vitiligo is a multifactorial disease caused by complex interactions between genetic and environmental factors [1][2][3]. The current data highlight the central role of immune cells and their mediators in the immunopathogenesis of vitiligo. The key immune cells include T helper 1 cells, cytotoxic T cells, regulatory and resident memory T cells, as well as dendritic cells (DCs), natural killer (NK) and ILC-1 cells. Moreover, key mediators such as interferon-γ (IFN-γ), C-X-C chemokine ligand 9 (CXCL9) and 10 (CXCL10), as well as interleukin-15 (IL-15) are also implicated in etiology of vitiligo [1][4][5]. Additionally, non-immune cells such as keratinocytes, fibroblasts, and stem cells contribute to vitiligo pathogenesis. However, the exact events leading to the development of vitiligo are still incompletely understood. Oxidative stress is currently accepted as the initial event leading to the activation of innate immunity in the earliest stages of vitiligo [6]. Genetic factors, together with environmental factors induce melanocyte and keratinocyte stress, represented by endoplasmic reticulum (ER) stress. Following exposure to stressful triggers, melanocytes release reactive oxygen species (ROS) which have the potential to alter cellular DNA, proteins, and lipids. This leads to the production of several damage-associated molecular patterns (DAMPs) such as melanocyte-specific antigens, miRNAs, and heat shock proteins (HSP) [6][7][8]. Inducible HSP protein 70 (iHSP70) is particularly important in bridging native and adaptive immunity since it can stimulate the transformation of dendritic cells into efficient antigen-presenting cells [9]. Dendritic cells (DC) present melanocyte-derived peptides to T cells leading to their differentiation and production of interferon-γ (IFN-γ) [7][9]. IFN-γ is the key cytokine mediator that leads to the phosphorylation of the transcription factor STAT1 by Janus kinases (JAK) 1 and 2. Phosphorylated STAT1 homodimerizes and enters the nucleus, where IFN-γ-dependent genes, such as CXCL9 and CXCL10 (C-X-C chemokine ligand 10), are transcribed [10][11]. CXCL9 and CXCL10 are responsible for the recruitment of autoreactive CD8+ T cells to the skin via their shared C-X-C chemokine receptor 3 (CXCR3) [11]. Impairment of regulatory T cells further enhances the CD8+ anti-melanocyte response. Finally, melanocyte apoptosis is mediated by granzyme B and perforin released from CD8+ T lymphocytes or alternatively via chemokine induction of the CXCR3B receptor on melanocytes [12][13][14].

2. The Role of Oxidative Stress

The skin functions as a barrier organ providing protection against external stressors. UV radiation, microorganisms, and oxidizing chemicals are examples of exogenous stimuli that target melanocytes and cause ROS production [6][7][15][16]. Thus, melanocytes employ several mechanisms to maintain redox homeostasis. Antioxidants, including superoxide dismutase, catalase, glutathione, vitamin C, and vitamin E may counteract the effects of ROS. Recent studies, however, have shown an imbalance in antioxidants, with higher levels of superoxide dismutase, lower levels of catalase, and increased lipid peroxidation in patients with vitiligo [6][7]. Additionally, elevated levels of ROS are found in both lesional and non-lesional skin of patients with vitiligo [17], further emphasizing their decreased ability to resist ROS [18]. Apart from exogenous sources of ROS, there are also endogenous ROS that mostly result from melanin synthesis [7][16]. However, vitiligo melanocytes exhibit several structural defects that impair their ability to resist oxidative stress, including endoplasmic reticulum dilatation, mitochondrial dysfunction, and abnormal melanosome structure [15]. Dilatation of the ER occurs because of the buildup of misfolded proteins, perpetuating ER stress and oxidative stress [19][20]. Additional instability of tyrosinase-related protein-1 (TYRP1), which is required for melanogenesis, leads to accumulation of melanin intermediates in patients with vitiligo [21][22][23]. Melanin intermediates, together with other stressors such as heat shock or ROS, disrupt the protein folding process in the ER, activating the unfolded protein response (UPR) and integrated stress response (ISR) [24][25]. UPR is one of the key factors driving the formation of neoantigens, which have the potential to activate innate immunity and eventually adaptive immunity against melanocytes [19][25]. The role of UPR has already been established in several autoimmune diseases, with type 1 diabetes (T1D) being one of the most studied [26][27]. In the skin and serum of patients with vitiligo, UPR promotes the production of the chemokines IL-6 and IL-8 through the transcription factor X-box-binding protein 1 (XBP1) [28]. Polymorphisms in UPR-linked genes, such as XBP1 and UVRAG, are associated with an increased risk of vitiligo [24][29]. The impaired function of the nuclear factor erythroid 2-related factor 2 (NRF2) antioxidant pathway further contributes to dysfunctional UPR activation in vitiligo. NRF2 is a nuclear factor employed in various antioxidant systems, such as the glutathione and thioredoxin antioxidant systems [30][31]. Since vitiligo melanocytes lack this protective antioxidant mechanism, they are vulnerable to the depigmenting chemical phenol monobenzone [32][33]. Therefore, targeting the NRF2 pathway may be a possible therapeutic option for patients with vitiligo [34][35].
Additional potential players in mediating oxidative stress response are small non-coding RNAs (ncRNAs), especially microRNAs (miRNAs) [36]. miRNAs regulate post-transcriptional gene expression by inducing degradation or inhibiting translation of mRNA to proteins [37]. Through targeting complex gene pathways, miRNA may provide a link to ER stress and appearance of vitiligo [38]. Previous studies have demonstrated alterations in multiple miRNAs expression affecting both skin and blood of patients with NSV [39]. MicroRNA421 (miR421) is one of the miRNAs associated with oxidative stress response in vitiligo. ER stress increases the expression of miR421 and several ER stress related proteins, whereas miR421 inhibition reduces the expression of ER stress related proteins and decreases melanocyte apoptosis. As a result, miR421 may be a promising therapeutic target for vitiligo [37]. The expression of miR-25 additionally increases in response to oxidative stress which causes degeneration of melanocytes but also alters keratinocytes’ protective paracrine function, and thus may be worth further investigation as a potential therapeutic target [40]. In contrast, miR-211, which is involved in mitochondrial metabolism and oxidative phosphorylation, is downregulated in vitiligo and may partly explain the increased ROS production and impaired respiratory responses seen in the disease [41]. Further research into various miRNAs and their target genes could provide useful insight into the molecular basis of vitiligo and even lead to the development of therapeutic targets or disease biomarkers.
Studies on melanocyte detachment mechanisms have recently emerged as an important factor in melanocyte loss. Notably, when IFN-γ and TNF-α are present, keratinocytes release matrix metalloproteinase (MMP)-9, which causes melanocyte detachment from the basal membrane by targeting E-cadherin. E-cadherin is a key protein involved in melanocyte adhesion. Interestingly, E-cadherin levels are lower in vitiligo patients’ perilesional skin, whereas MMP-9 levels are higher in the skin and sera of patients with vitiligo [42][43]. Another protein with similar function is the melanoma inhibitory activity (MIA) protein, which targets alpha5beta1 integrins (a5b1ints) and can induce melanocyte detachment. The presence of MIA in vitiligo patients has already been established [44]. A recent study on the vitiligo mouse model revealed that the introduction of MIA resulted in the formation of a depigmentation zone that histologically corresponded to vitiligo. However, because there were no immune cells in this vitiligo model, it is unclear how MIA is related to oxidative stress or immune-mediated vitiligo mechanisms. Perhaps, IFN-γ or oxidative stress may be responsible for inducing melanocyte senescence followed by release of MIA which is yet to be investigated [45].
Despite the lack of specific mechanisms underlying the link between innate immunity and oxidative stress, oxidative stress provides a plausible explanation for the onset of vitiligo and subsequent activation of innate immunity.

3. The Role of Innate Immunity

Innate immunity is frequently referred to as a bridge between oxidative stress and adaptive immunity [46]. That is due to the ability of innate immune cells to recognize stressed or damaged cells via pattern recognition receptors (PRRs) [5][47]. Among the cells of innate immunity, NK cells and DCs are the most studied in vitiligo. Previous studies have found systemic and local increase in the function and expression of NK cells [12][13][48]. In addition to NK cells, DCs are additional players in the innate immunity through recognition of DAMPs released by stressed melanocytes. Following DC maturation, melanocyte-associated antigens are presented to T cells in lymphoid tissues, resulting in a T-cell mediated anti-melanocyte response [9][28][49]. In addition, increased levels of innate immunity cytokines including interleukin (IL)-1α, IL-1β, IL-6, IL-8, IL-12, IL-15 and tumor necrosis factor (TNF)-α have been detected in the sera of patients with vitiligo [50]. Evidence on the role of innate immunity has furthermore been established from genetic studies showing upregulation of genes involved in innate immunity in the lesional and non-lesional skin of vitiligo patients [48]. Additionally, genes related to innate immunity including NALP1, TICAM1, IFIH1 are recognized as vitiligo susceptibility genes [46][51][52][53][54]. As suggested above, the innate immunity pathways are certainly implicated in the onset and progression of vitiligo.

3.1. The Role of DAMPs and PAMPs

The accumulation of ROS in melanocytes under oxidative stress has the potential for carbonylation and oxidation of melanocyte proteins, leading to the formation of neoantigens or DAMPs [55]. Pattern recognition receptors (PRRs) such as Toll-like receptors (TLR), RIG-I-like receptors (RLRs), and nucleotide oligomerization domain (NOD)-like receptors (NLRs) allow cells of the innate immune system to recognize stressed or damaged melanocytes [56][57]. HSP70 is one of the most recognized DAMPs in vitiligo, correlating well with disease activity [9]. Exposure to certain chemicals such as 4-tertiary butyl-phenol (4-TBP) may induce the production of HSP70 by vitiligo melanocytes [9][58]. Vitiligo melanocytes consequently express tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) on their surface, leading to the infiltration of DCs into the perilesional skin of patients with vitiligo. Recently, a study on vitiligo in a Sinclair swine model found that the altered version of iHSP70, that is, HSP70iQ435A may induce the repigmentation of vitiligo lesions, thus making it a potential therapeutic target [59]. Another important DAMP is the high-mobility group protein B1 (HMGB1), which can mediate oxidative stress response and activation of DCs [55]. HMBG1 is released from both activated immune or non-immune cells such as melanocytes and keratinocytes, and levels of HMBG1 are increased in sera and lesional skin of patients with active vitiligo [31][60]. The key mediators of HMGB1, CXCL16, and IL-8, produced by keratinocytes lead to CD8+ T-cell chemotaxis and infiltration of the perilesional skin [60][61]. In addition to HSP70 and HMGB1, calreticulin (CRT) is also a messenger of the melanocyte oxidative response. CRT is an ER protein employed in Ca2+ homeostasis and signaling. CRT can enhance the immunogenicity of melanocytes directly by increasing its expression on their surface or indirectly through the induction of several cytokines, such as IL-6 and TNFα. This subsequently leads to apoptosis of melanocytes and further activation of innate immune cells [62].
There is additional evidence linking viral and bacterial infections to the development of vitiligo [63][64]. Since innate cells can recognize viral and bacterial components, commonly known as pathogen-associated molecular patterns (PAMPs), they can also serve as a pathway for their activation. Although several viral agents such as human immunodeficiency virus (HIV), herpes simplex viruses (HSV), varicella zoster virus (VZV), Epstein–Barr virus (EBV), and cytomegalovirus (CMV) have been investigated in context of vitiligo, their role in vitiligo remains unclear. Interestingly, recent study reported increased expression of cytosolic viral sensor MDA5 and anti-CMV IgM in patients with progressive vitiligo. MDA5 is encoded by IFIH1 which is recognized as one of the vitiligo susceptibility genes. Viral infection may activate MDA5 leading to the production of CXCL10 and CXCL16 by keratinocytes and recruitment of CD8+ T cells into the skin [54]. The impact of bacterial infections on vitiligo is currently uncertain although there are studies linking gut-skin dysbiosis to the appearance of vitiligo lesions and evidence of lesional skin dysbiosis compared to non-lesional skin in patients with vitiligo [64][65][66]. To summarize, although the evidence of the PAMPs activation pathway in vitiligo is still limited, it is certainly worth investigating given the link between other immune-mediated skin diseases and infectious triggers.

3.2. Dendritic Cells (DCs)

DCs play a role in connecting oxidative stress with the adaptive immune response in vitiligo. They are antigen presenting cells (APC) responsible for T-cell activation, cytokine production, and immune response regulation. Following the recognition of DAMPs, such as HSP70i, DCs release high levels of IFN-α [67]. IFN-α induces the production of CXCL9 and CXCL10 by keratinocytes, thereby orchestrating the differentiation of T helper (Th) cells into the Th1 phenotype [68]. The role of plasmacytoid DCs (pDCs) as potent producers of IFN type I has been established in vitiligo. In active vitiligo lesions, PDCs expressing the HSP70 receptor, Lox-1, are primarily found near keratinocytes expressing HSP70. Furthermore, exogenous HSP70 can directly activate pDCs and induce IFN-α production, as demonstrated by the infiltrates of DCs and increased levels of IFN-α in the perilesional skin of patients with vitiligo [49][68]. However, a recent study found decreased levels of IFN-α in the circulation of patients with vitiligo, and increased levels of circulating DCs, IL-12, and TNF-α in patients with non-segmental vitiligo [69]. Another study demonstrated a relationship between the production of pro- and anti-inflammatory cytokines (IL-17A, IL-10, and IL-12p70) by DCs in both stable and active patients with vitiligo. The researchers discovered that individuals with active vitiligo had higher levels of pro-inflammatory DCs (CD11b+CD11c+) in their peripheral blood mononuclear cells (PBMCs) and their skin than patients with stable vitiligo [9][70]. Interestingly, the levels of anti-inflammatory DC (CD11b+) and anti-inflammatory cytokine IL-10 were decreased in patients with active vitiligo, in contrast to an increased level of the pro-inflammatory cytokine IL-17A [70]. This latest data highlights the role of DCs in progression of vitiligo through modulation of pro- and anti-inflammatory cytokines.

3.3. Natural Killer (NK) Cells and Innate Lymphoid Cells Type 1 (ILC-1)

Natural killer (NK) cells are involved in the early development of vitiligo as key initiators of the adaptive immune response [13]. NK cells, together with the innate lymphoid cells type 1 (ILC-1) are members of innate lymphocytes that form the first line of defense against infectious triggers and tumor cells [13][71][72]. In addition, NK cells possess a cytotoxic and regulatory function and are able to identify and destroy cells exposed to stress through activation receptors or limit the immune response through inhibitory receptors [72]. Previous studies have found elevated levels of circulating NK cells in patients with vitiligo; however, their role in the development of vitiligo was unclear, until recently [73][74]. Recent data indicate increase in basal expression of NK and ILC-1 cells in the perilesional skin and blood of patients with vitiligo [13]. In addition, NK cells receptors, including natural killer cell triggering receptor (NKTR), killer cell lectin-like receptor C1 (KLRC1), CCL20, and NK cell-related cytokines such as TNFα and IL-15, are also increased in perilesional skin in patients with vitiligo [75]. These data are consistent with the first analysis of the transcriptome of vitiligo skin genes, which showed increased expression of genes associated with the innate immune response, especially the function and activity of NK cells [48]. Furthermore, NK cells produce a wide range of cytokines and chemokines that aid in recruitment and activation of the adaptive immune cells [72]. In response to oxidative stress, as well as DAMP molecules such as HSP70 and HMBG1, NK and ILC-1 increase their production of IFN-γ in patients with vitiligo [13]. In addition, stressed NK and ILC-1 cells are able to induce keratinocyte and melanocyte production of chemokines CXCL9, CXCL10, CXCL11 and IFN-γ [13]. Therefore, it seems that NK cells, together with ILC-1, play a key role in the initial steps of vitiligo by modulating melanocyte and keratinocyte oxidative response resulting in production of IFN-γ and chemokines with consequent infiltration of CD8+ melanocyte-specific T lymphocytes.

4. Adaptive Immunity

4.1. Cytotoxic CD8+ T cells

Vitiligo is a complex immune-mediated disease in which cytotoxic T lymphocytes target melanocytes, resulting in skin depigmentation. Although the immunopathogenesis of vitiligo remains unresolved, cytotoxic T-lymphocytes play a central role in the onset and clinical course of the disease. CD8+ T lymphocytes infiltrate vitiligo lesions, where they specifically target melanocytes [76][77][78][79]. Autoreactive CD8+ T lymphocytes produce interferon-gamma (IFN-γ), as demonstrated by its increased levels in vitiligo lesions [78]. IFN-γ-dependent mobilization of T cells to peripheral tissues involves the stimulation of chemokine secretion and expression of adhesion molecules on endothelial cells in skin lesions. Furthermore, IFN-γ stimulates the secretion of CXCL9 and CXCL10 by keratinocytes, which are responsible for guiding antigen-specific autoreactive CD8+ T lymphocytes into the skin and for inducing their effector functions [13][80]. Increased expression of the chemokines CXCL9 and CXCL10 and their associated CXCR3 receptor has been observed in vitiligo [11] (6). The levels of CXCL9 and CXCL10 correlate with clinical activity, whereas CXCL10 is linked to severity of the disease [11][80]. The accumulation of CD8+ T lymphocytes near epidermal melanocytes constitutes the effector phase of the anti-melanocyte response in vitiligo. Infiltrates of T lymphocytes, predominantly of the CD8+ phenotype, in addition to CD4+ T lymphocytes, were found in the lesions of patients with vitiligo, indicating an anti-melanocyte response mediated by CD8+ T lymphocytes [81]. Stimulation with melanocyte-specific antigens leads to the activation of CD8+ T lymphocytes, as demonstrated by the increased expression of cytotoxic markers such as granzyme-B, perforin, IFN-γ, and tumor necrosis factor-alpha (TNF-α, from tumor necrosis factor-alpha) [82]. Finally, CD8+ T lymphocytes produce increased levels of granzyme B, perforin, and IFN-γ, and highly express apoptosis stimulation fragment ligand (FasL) causing melanocyte death [14]. In addition to the aforementioned cytolytic molecules, recent data indicate another pathway of melanocyte apoptosis via chemokine-receptor-3 (CXCR3) isoform B CXCR3B. CXCR3B is found on the surface of melanocytes, and binding of its ligand, CXCL10, leads to melanocyte apoptosis. This apoptotic pathway is amplified in the presence of CD8+ lymphocytes [12][13].

4.2. Regulatory T Cells

Regulatory T cells (Tregs) are CD4+ T cells crucial for providing peripheral tolerance to self-antigens by suppressing self-reactive CD8+ T cells. They inhibit the effector functions of T-cell directly by cell to cell contact or through the secretion of inhibitory cytokines [83]. Tregs are distinguished by the expression of CD4+, CD25+, and forkhead box P3 protein (FOXP3) [84][85]. The current literature on vitiligo places alterations in the number and function of Treg cells as important factors to the development of vitiligo. Previous research suggests an altered ratio of Treg cells in favor of CD8+ T cells, which may lead to sustained activation of anti-melanocyte CD8+ T cells [86][87]. In addition, Treg expression is reduced even beyond the borders of depigmentation in vitiligo skin, thus allowing CD8+ to attack melanocytes [88][89]. The lack of Tregs in vitiligo is caused by a decrease in the Treg homing receptor CCL22 in the skin of vitiligo patients [88][89]. Interestingly, by introducing CCL22 into the skin it was possible to cease depigmentation in a mouse model of vitiligo [88][89][90]. Tregs from active vitiligo lesions bear several functional defects, as evidenced by lower expression of immunosuppressive cytokines such as TGF-β and the transcription factor FoxP3 [85][87][91]. FoxP3 is important for its role in cytokine modulation as it increases the expression of immunosuppressive molecules such as CD25 and CTLA-4 while decreasing the expression of IL-2 and IL-4, which are required for T-cell activation [91]. However, more research is needed to determine the role of Tregs in vitiligo as well as therapeutic strategies based on modulating Tregs function.

4.3. Tissue-Resident Memory T Cells

Tissue-resident memory T (TRM) cells comprise a diverse population of non-recirculating memory T cells important for assuring localized protection against reinfection with pathogens or foreign antigens [92][93][94]. Their role in many immune-mediated skin diseases, including vitiligo, has recently been apostrophized. The clinical course of vitiligo is marked by periods of stable disease, often complicated by periods of relapse in areas previously affected by vitiligo. Autoreactive skin TRM are thought to be responsible for vitiligo relapses in the event of different triggers. The population of TRM has already been demonstrated in the lesional and non-lesional skin of patients with vitiligo [95][96][97]. Skin TRM are characterized by the expression of CD69 (a C-type lectin), CD103 (integrin αE), and facultative expression of CD49a [94][95][98]. Interestingly, recent studies have revealed the presence of melanocyte-specific CD8+ TRM in the perilesional skin of patients with stable and active vitiligo [99]. This indicates their endurance in the skin following T-cell-driven inflammation and their ability to modulate future relapses or sustain depigmentation. The CD4+ TRM cells are present in the dermis, whereas melanocyte-specific CD8+ TRM are located in the epidermis of perilesional skin, near the melanocytes of patients with vitiligo [97][99]. CD8+ TRM are potent producers of IFN-γ and TNFα, which induce keratinocytes for CXCL9 and CXCL10 production and additional TRM influx into the skin. The recruitment of TRM cells to the skin is mediated by the CXCR3 receptor through its ligands, CXCL9 and CXCL10 [97][100][101]. CD49a has recently been identified as a marker of cytotoxic CD8+ TRM cells, which are potent producers of IFN-γ. However, their expression of key cytotoxic mediators, such as perforin and granzyme, relies on IL-15 production by keratinocytes and innate immune cells. In addition, CD8+ TRM express the C-type lectin-like receptor Natural Killer Group 2D (NKG2D) which is a marker of their activation [95][96][100]. Another interesting finding is the presence of melanocyte-specific but not activated TRM cells in the non-lesional skin of patients with vitiligo [96]. These cells could potentially lead to the emergence of new vitiligo lesions if appropriate triggers are present [97].

4.4. The Role of B-Lymphocytes

In addition to T-cell mediated immunity, humoral pathways have been linked to the immunopathogenesis of vitiligo. B-cells are increased in epidermis of patients with vitiligo compared to healthy controls [102]. Additionally, there is evidence on a number of melanocyte-specific antibodies found in the sera of vitiligo patients which correlate with the disease’s activity. The presence of anti-melanocyte antibodies indicates a systemic immune activation in non-segmental vitiligo [103][104]. Furthermore, recent study revealed increased proportion of circulating memory B cells and decreased levels of naive B cells in active vitiligo, which is followed by an increase in circulating T follicular helper (cTfh) cells [105]. However, more research is needed to determine the precise function of B-cells and humoral mechanisms in vitiligo.

5. Main Cytokine Networks

The main cytokine networks explored in the pathogenesis of vitiligo are IFN-γ and TNF-α, in addition to IL-15 and Th17-related cytokines such as IL-17 and IL-23. The IFN-γ signalling pathway is well established in the pathogenesis of vitiligo, especially during the initiation of the disease. The major producers of IFN-γ are NK and ILC-1 cells, which are increased in the blood and non-lesional skin of vitiligo patients [13]. The main triggers leading to IFN-γ production are ROS, Hsp70i, and HMGB1, resulting in the increased expression of CXCR3B by melanocytes, as well as CXCL9 and CXCL10 by keratinocytes [13]. CXCL9 and CXCL10 are CXCR3 ligands that are important for the recruitment of adaptive immune cells to the skin and progression of vitiligo [106]. IFN-γ operates through the JAK/STAT pathway, resulting in the activation of JAK1-2 and STAT1 [5]. The JAK/STAT pathway consists of JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2), which mediate cytokine signaling and induce innate and adaptive responses. Specifically, IFN-α activates JAK1/TYK2 and IFN-γ mediates its effects through JAK1/JAK2, IL-2, and IL-15 by initiating the JAK1/JAK3 pathway. The importance of the JAK pathway in vitiligo pathogenesis is evidenced by promising results achieved with JAK inhibitors in ongoing clinical trials. TNF-α, on the other hand, mediates its action through receptors TNFR1 or TNFR2, leading to the induction of mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-kB) pathways [107]. Although it would be reasonable to propose TNF-α inhibitors for the treatment of vitiligo, the results of TNF-α inhibitors for treatment of vitiligo are not promising and even resulted in worsening of vitiligo [107]. Together, IFN-γ and TNF-α play a role in interfering with melanogenesis by directly decreasing the process of pigmentation. The combined role of these two cytokines was clearly evident in a recent study showing disruption of E-cadherin, resulting in the detachment of melanocytes from the basal layer of the epidermis in the presence of IFN-γ and TNF-α [43]. Another important pathway is the IL-15 cytokine pathway which has recently emerged in the pathogenesis of vitiligo, particularly through its role in the regulation of TRM [95][98]. IL-15 mediates its actions through the CD122 receptor subunit found on the surface of TRM. IL-15 is primarily produced by epidermal basal keratinocytes. Furthermore, IL-15R, which is essential for IL-15 transpresentation, is increasingly expressed by perilesional keratinocytes in patients with vitiligo [108]. Recent data linked the oxidative stress to an increased expression of IL-15 and IL-15Rα in the epidermis of vitiligo patients. In addition, IL-15 is able to intensify the cytotoxic potential of CD49a+ TRM cells, as well as the production of IFN-γ, the major driver of vitiligo [95]. The relevance of the IL-15 pathway is further evident from the promising results achieved through inhibition of IL-15 in a mouse model of vitiligo [96]. Another cytokine axis explored in the context of vitiligo is the IL-23/IL-17 axis [109]. Some in vitro studies have demonstrated IL-17 ability to shrink melanocytes, inhibit melanogenesis, and induce autophagy by impairing mitochondrial function via cytokines IL-1β, IL-6, and TNF-α [110]. Furthermore, there is evidence of an increase in Th17 lymphocytes, IL-17, and IL-23 levels in the serum and skin of vitiligo patients [111]. Recent studies, on the other hand, have found no evidence of elevated IL-17 levels in skin of patients with vitiligo when compared to healthy or psoriatic skin [97]. Furthermore, in a single-arm pilot study, the IL-17A inhibitor secukinumab failed to produce clinical results in the treatment of vitiligo and even worsened the condition in the majority of patients [112]. Therefore, the role of IL-17 pathway in the development of vitiligo remains to be elucidated.

References

  1. Seneschal, J.; Boniface, K.; D’Arino, A.; Picardo, M. An update on Vitiligo pathogenesis. Pigment Cell Melanoma Res. 2021, 34, 236–243.
  2. Boniface, K.; Seneschal, J.; Picardo, M.; Taïeb, A. Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy. Clin. Rev. Allergy Immunol. 2018, 54, 52–67.
  3. Strassner, J.; Harris, J.E. Understanding mechanisms of autoimmunity through translational research in vitiligo. Curr. Opin. Immunol. 2016, 43, 81–88.
  4. Bergqvist, C.; Ezzedine, K. Vitiligo: A Review. Dermatology 2020, 236, 571–592.
  5. Migayron, L.; Boniface, K.; Seneschal, J. Vitiligo, From Physiopathology to Emerging Treatments: A Review. Dermatol. Ther. 2020, 10, 1185–1198.
  6. Xuan, Y.; Yang, Y.; Xiang, L.; Zhang, C. The Role of Oxidative Stress in the Pathogenesis of Vitiligo: A Culprit for Melanocyte Death. Oxidative Med. Cell. Longev. 2022, 2022, 8498472.
  7. Wang, Y.; Li, S.; Li, C. Perspectives of New Advances in the Pathogenesis of Vitiligo: From Oxidative Stress to Autoimmunity. Med. Sci. Monit. 2019, 25, 1017–1023.
  8. Speeckaert, R.; Dugardin, J.; Lambert, J.; Lapeere, H.; Verhaeghe, E.; Speeckaert, M.; Van Geel, N. Critical appraisal of the oxidative stress pathway in vitiligo: A systematic review and meta-analysis. J. Eur. Acad. Dermatol. Venereol. 2018, 32, 1089–1098.
  9. Mosenson, J.A.; Flood, K.; Klarquist, J.; Eby, J.M.; Koshoffer, A.; Boissy, R.E.; Overbeck, A.; Tung, R.C.; Le Poole, I.C. Preferential secretion of inducible HSP70 by vitiligo melanocytes under stress. Pigment Cell Melanoma Res. 2013, 27, 209–220.
  10. Harris, J.E.; Harris, T.H.; Weninger, W.; Wherry, E.J.; Hunter, C.A.; Turka, L.A. A Mouse Model of Vitiligo with Focused Epidermal Depigmentation Requires IFN-γ for Autoreactive CD8+ T-Cell Accumulation in the Skin. J. Investig. Dermatol. 2012, 132, 1869–1876.
  11. Wang, X.X.; Wang, Q.Q.; Wu, J.Q.; Jiang, M.; Chen, L.; Zhang, C.F.; Xiang, L.H. Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo. Br. J. Dermatol. 2016, 174, 1318–1326.
  12. Passeron, T.; Malmqvst, V.E.; Bzioueche, H.; Marchetti, S.; Rocchi, S.; Tulic, M.K. Increased Activation of Innate Immunity and Pro-Apoptotic CXCR3B in Normal-Appearing Skin on the Lesional Site of Patients with Segmental Vitiligo. J. Investig. Dermatol. 2021, 142, 480–483.e2.
  13. Tulic, M.K.; Cavazza, E.; Cheli, Y.; Jacquel, A.; Luci, C.; Cardot-Leccia, N.; Hadhiri-Bzioueche, H.; Abbe, P.; Gesson, M.; Sormani, L.; et al. Innate lymphocyte-induced CXCR3B-mediated melanocyte apoptosis is a potential initiator of T-cell autoreactivity in vitiligo. Nat. Commun. 2019, 10, 2178.
  14. Hassan, A.S.; Kohil, M.M.; Sayed, S.S.E.; Mahmoud, S.B. Immunohistochemical study of perforin and apoptosis stimulation fragment ligand (FasL)in active vitiligo. Arch. Dermatol. Res. 2021, 313, 453–460.
  15. Rashighi, M.; Harris, J.E. Vitiligo Pathogenesis and Emerging Treatments. Dermatol. Clin. 2017, 35, 257–265.
  16. Xie, H.; Zhou, F.; Liu, L.; Zhu, G.; Li, Q.; Li, C.; Gao, T. Vitiligo: How do oxidative stress-induced autoantigens trigger autoimmunity? J. Dermatol. Sci. 2016, 81, 3–9.
  17. He, Y.; Li, S.; Zhang, W.; Dai, W.; Cui, T.; Wang, G.; Gao, T.; Li, C. Dysregulated autophagy increased melanocyte sensitivity to H2O2-induced oxidative stress in vitiligo. Sci. Rep. 2017, 7, 42394.
  18. Schallreuter, K.U.; Moore, J.; Wood, J.M.; Beazley, W.D.; Gaze, D.C.; Tobin, D.; Marshall, H.S.; Panske, A.; Panzig, E.; Hibberts, N.A. In Vivo and In Vitro Evidence for Hydrogen Peroxide (H2O2) Accumulation in the Epidermis of Patients with Vitiligo and its Successful Removal by a UVB-Activated Pseudocatalase. J. Investig. Dermatol. Symp. Proc. 1999, 4, 91–96.
  19. Jadeja, S.D.; Mayatra, J.M.; Vaishnav, J.; Shukla, N.; Begum, R. A Concise Review on the Role of Endoplasmic Reticulum Stress in the Development of Autoimmunity in Vitiligo Pathogenesis. Front. Immunol. 2021, 11, 624566.
  20. Tu, B.P.; Weissman, J.S. Oxidative protein folding in eukaryotes. J. Cell Biol. 2004, 164, 341–346.
  21. Wong, P.M.; Yang, L.; Wu, H.; Li, W.; Ma, X.; Katayama, I.; Zhang, H. New insight into the role of exosomes in vitiligo. Autoimmun. Rev. 2020, 19, 102664.
  22. Zhang, J.; Yu, R.; Guo, X.; Zou, Y.; Chen, S.; Zhou, K.; Chen, Y.; Li, Y.; Gao, S.; Wu, Y. Identification of TYR, TYRP1, DCT and LARP7 as related biomarkers and immune infiltration characteristics of vitiligo via comprehensive strategies. Bioengineered 2021, 12, 2214–2227.
  23. Jimbow, K.; Chen, H.; Park, J.S.; Thomas, P.D. Increased sensitivity of melanocytes to oxidative stress and abnormal expression of tyrosinase-related protein in vitiligo. Br. J. Dermatol. 2001, 144, 55–65.
  24. Manga, P.; Choudhury, N. The unfolded protein and integrated stress response in melanoma and vitiligo. Pigment Cell Melanoma Res. 2020, 34, 204–211.
  25. Shpilka, T.; Haynes, C.M. The mitochondrial UPR: Mechanisms, physiological functions and implications in ageing. Nat. Rev. Mol. Cell Biol. 2017, 19, 109–120.
  26. Shrestha, N.; Reinert, R.B.; Qi, L. Endoplasmic Reticulum Protein Quality Control in β Cells. Semin. Cell Dev. Biol. 2020, 103, 59–67.
  27. Todd, D.J.; Lee, A.H.; Glimcher, L.H. The endoplasmic reticulum stress response in immunity and autoimmunity. Nat. Rev. Immunol. 2008, 8, 663–674.
  28. Toosi, S.; Orlow, S.; Manga, P. Vitiligo-Inducing Phenols Activate the Unfolded Protein Response in Melanocytes Resulting in Upregulation of IL6 and IL8. J. Investig. Dermatol. 2012, 132, 2601–2609.
  29. Singh, M.; Jadeja, S.D.; Vaishnav, J.; Mansuri, M.S.; Shah, C.; Mayatra, J.M.; Shah, A.; Begum, R. Investigation of the Role of Interleukin 6 in Vitiligo Pathogenesis. Immunol. Investig. 2020, 51, 120–137.
  30. Gorrini, C.; Baniasadi, P.S.; Harris, I.S.; Silvester, J.; Inoue, S.; Snow, B.; Joshi, P.A.; Wakeham, A.; Molyneux, S.D.; Martin, B.; et al. BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. J. Exp. Med. 2013, 210, 1529–1544.
  31. Mou, K.; Liu, W.; Miao, Y.; Cao, F.; Li, P. HMGB1 deficiency reduces H2O2-induced oxidative damage in human melanocytes via the Nrf2 pathway. J. Cell Mol. Med. 2018, 22, 6148–6156.
  32. Arowojolu, O.A.; Orlow, S.; Elbuluk, N.; Manga, P. The nuclear factor (erythroid-derived 2)-like 2 (NRF2) antioxidant response promotes melanocyte viability and reduces toxicity of the vitiligo-inducing phenol monobenzone. Exp. Dermatol. 2017, 26, 637–644.
  33. van den Boorn, J.G.; Picavet, D.I.; van Swieten, P.F.; van Veen, H.A.; Konijnenberg, D.; van Veelen, P.A.; van Capel, T.; Jong, E.C.D.; Reits, E.A.; Drijfhout, J.W.; et al. Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J. Investig. Dermatol. 2011, 131, 1240–1251.
  34. Jian, Z.; Tang, L.; Yi, X.; Liu, B.; Zhang, Q.; Zhu, G.; Wang, G.; Gao, T.; Li, C. Aspirin induces Nrf2-mediated transcriptional activation of haem oxygenase-1 in protection of human melanocytes from H2O2-induced oxidative stress. J. Cell. Mol. Med. 2016, 20, 1307–1318.
  35. Chang, Y.; Li, S.; Guo, W.; Yang, Y.; Zhang, W.; Zhang, Q.; He, Y.; Yi, X.; Cui, T.; An, Y.; et al. Simvastatin Protects Human Melanocytes from H2O2-Induced Oxidative Stress by Activating Nrf2. J. Investig. Dermatol. 2017, 137, 1286–1296.
  36. Zhou, T.; Li, D.; Deng, Y. Update on the role of noncoding RNAs in vitiligo. Chin. Med. J. 2021, 135, 793–795.
  37. Sun, X.; Wang, T.; Huang, B.; Ruan, G.; Xu, A. ΜicroRNA-421 participates in vitiligo development through regulating human melanocyte survival by targeting receptor-interacting serine/threonine kinase 1. Mol. Med. Rep. 2020, 21, 858–866.
  38. Mansuri, M.S.; Singh, M.; Begum, R. miRNA signatures and transcriptional regulation of their target genes in vitiligo. J. Dermatol. Sci. 2016, 84, 50–58.
  39. Mansuri, M.S.; Singh, M.; Dwivedi, M.; Laddha, N.C.; Marfatia, Y.S.; Begum, R. MicroRNA profiling reveals differentially expressed microRNA signatures from the skin of patients with nonsegmental vitiligo. Br. J. Dermatol. 2014, 171, 1263–1267.
  40. Shi, Q.; Zhang, W.; Guo, S.; Jian, Z.; Li, S.; Li, K.; Ge, R.; Dai, W.; Wang, G.; Gao, T.; et al. Oxidative stress-induced overexpression of miR-25: The mechanism underlying the degeneration of melanocytes in vitiligo. Cell Death Differ. 2015, 23, 496–508.
  41. Sahoo, A.; Lee, B.; Boniface, K.; Seneschal, J.; Sahoo, S.K.; Seki, T.; Wang, C.; Das, S.; Han, X.; Steppie, M.; et al. MicroRNA-211 Regulates Oxidative Phosphorylation and Energy Metabolism in Human Vitiligo. J. Investig. Dermatol. 2017, 137, 1965–1974.
  42. Delmas, V.; Larue, L. Molecular and cellular basis of depigmentation in vitiligo patients. Exp. Dermatol. 2018, 28, 662–666.
  43. Boukhedouni, N.; Martins, C.; Darrigade, A.S.; Drullion, C.; Rambert, J.; Barrault, C.; Garnier, J.; Jacquemin, C.; Thiolat, D.; Lucchese, F.; et al. Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo. JCI Insight. 2020, 5, e133772.
  44. Bordignon, M.; Castellani, C.; Fedrigo, M.; Thiene, G.; Peserico, A.; Alaibac, M.; Angelini, A. Role of alpha5beta1 integrin and MIA (melanoma inhibitory activity) in the pathogenesis of vitiligo. J. Dermatol. Sci. 2013, 71, 142–145.
  45. Bordignon, M.; Luisetto, R.; Valente, M.L.; Fedrigo, M.; Castellani, C.; Angelini, A.; Alaibac, M. Melanoma Inhibitory Activity (MIA) Is Able to Induce Vitiligo-Like Depigmentation in an in vivo Mouse Model by Direct Injection in the Tail. Front. Med. 2020, 7, 430.
  46. Boniface, K.; Passeron, T.; Seneschal, J.; Tulic, M.K. Targeting Innate Immunity to Combat Cutaneous Stress: The Vitiligo Perspective. Front. Immunol. 2021, 12, 613056.
  47. Faraj, S.; Kemp, E.H.; Gawkrodger, D.J. Patho-immunological mechanisms of vitiligo: The role of the innate and adaptive immunities and environmental stress factors. Clin. Exp. Immunol. 2021, 207, 27–43.
  48. Yu, R.; Broady, R.; Huang, Y.; Wang, Y.; Yu, J.; Gao, M.; Levings, M.; Wei, S.; Zhang, S.; Xu, A.; et al. Transcriptome Analysis Reveals Markers of Aberrantly Activated Innate Immunity in Vitiligo Lesional and Non-Lesional Skin. PLoS ONE 2012, 7, e51040.
  49. Bertolotti, A.; Boniface, K.; Vergier, B.; Mossalayi, D.; Taieb, A.; Ezzedine, K.; Seneschal, J. Type I interferon signature in the initiation of the immune response in vitiligo. Pigment Cell Melanoma Res. 2014, 27, 398–407.
  50. Gholijani, N.; Yazdani, M.-R.; Dastgheib, L. Predominant role of innate pro-inflammatory cytokines in vitiligo disease. Arch. Dermatol. Res. 2019, 312, 123–131.
  51. Jin, Y.; Mailloux, C.M.; Gowan, K.; Riccardi, S.L.; Laberge, G.; Bennett, D.C.; Fain, P.R.; Spritz, R.A. NALP1in Vitiligo-Associated Multiple Autoimmune Disease. N. Engl. J. Med. 2007, 356, 1216–1225.
  52. Spritz, R.A.; Santorico, S.A. The Genetic Basis of Vitiligo. J. Investig. Dermatol. 2021, 141, 265–273.
  53. Jin, Y.; Andersen, G.; Yorgov, D.; Ferrara, T.M.; Ben, S.; Brownson, K.M.; Holland, P.J.; Birlea, S.A.; Siebert, J.; Hartmann, A.; et al. Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants. Nat. Genet. 2016, 48, 1418–1424.
  54. Zhuang, T.; Yi, X.; Chen, J.; Kang, P.; Chen, X.; Chen, J.; Cui, T.; Chang, Y.; Ye, Z.; Ni, Q.; et al. Intracellular virus sensor MDA5 exacerbates vitiligo by inducing the secretion of chemokines in keratinocytes under virus invasion. Cell Death Dis. 2020, 11, 453.
  55. Frisoli, M.L.; Essien, K.; Harris, J.E. Vitiligo: Mechanisms of Pathogenesis and Treatment. Annu. Rev. Immunol. 2020, 38, 621–648.
  56. Levandowski, C.B.; Mailloux, C.M.; Ferrara, T.M.; Gowan, K.; Ben, S.; Jin, Y.; McFann, K.K.; Holland, P.J.; Fain, P.R.; Dinarello, C.A.; et al. NLRP1 haplotypes associated with vitiligo and autoimmunity increase interleukin-1β processing via the NLRP1 inflammasome. Proc. Natl. Acad. Sci. USA 2013, 110, 2952–2956.
  57. Traks, T.; Keermann, M.; Karelson, M.; Rätsep, R.; Reimann, E.; Silm, H.; Vasar, E.; Kõks, S.; Kingo, K. Polymorphisms in Toll-like receptor genes are associated with vitiligo. Front. Genet. 2015, 6, 278.
  58. Doss, R.W.; El-Rifaie, A.-A.A.; Abdel-Wahab, A.M.; Gohary, Y.M.; Rashed, L.A. Heat shock protein-70 expression in vitiligo and its relation to the disease activity. Indian J. Dermatol. 2016, 61, 408–412.
  59. Henning, S.W.; Fernandez, M.F.; Mahon, J.P.; Duff, R.; Azarafrooz, F.; Guevara-Patiño, J.A.; Rademaker, A.W.; Salzman, A.L.; Le Poole, I.C. HSP70iQ435A-Encoding DNA Repigments Vitiligo Lesions in Sinclair Swine. J. Investig. Dermatol. 2018, 138, 2531–2539.
  60. Cui, T.; Zhang, W.; Li, S.; Chen, X.; Chang, Y.; Yi, X.; Kang, P.; Yang, Y.; Chen, J.; Liu, L.; et al. Oxidative Stress–Induced HMGB1 Release from Melanocytes: A Paracrine Mechanism Underlying the Cutaneous Inflammation in Vitiligo. J. Investig. Dermatol. 2019, 139, 2174–2184.e4.
  61. Kim, J.; Lee, E.; Seo, J.; Oh, S.H. Impact of high-mobility group box 1 on melanocytic survival and its involvement in the pathogenesis of vitiligo. Br. J. Dermatol. 2017, 176, 1558–1568.
  62. Zhang, Y.; Liu, L.; Jin, L.; Yi, X.; Dang, E.; Yang, Y.; Li, C.; Gao, T. Oxidative Stress–Induced Calreticulin Expression and Translocation: New Insights into the Destruction of Melanocytes. J. Investig. Dermatol. 2014, 134, 183–191.
  63. Dwivedi, M.; Laddha, N.C.; Begum, R. Viral causes of Vitiligo: A New Perspective for Vitiligo Pathogenesis. Virol. Immunol. J. 2018, 2, 000181.
  64. Ganju, P.; Nagpal, S.; Mohammed, M.H.; Kumar, P.N.; Pandey, R.; Natarajan, V.T.; Mande, S.S.; Gokhale, R.S. Microbial community profiling shows dysbiosis in the lesional skin of Vitiligo subjects. Sci. Rep. 2016, 6, 18761.
  65. Dellacecca, E.R.; Cosgrove, C.; Mukhatayev, Z.; Akhtar, S.; Engelhard, V.H.; Rademaker, A.W.; Knight, K.L.; Le Poole, I.C. Antibiotics Drive Microbial Imbalance and Vitiligo Development in Mice. J. Investig. Dermatol. 2020, 140, 676–687.e6.
  66. Bzioueche, H.; Simonyté Sjödin, K.; West, C.E.; Khemis, A.; Rocchi, S.; Passeron, T.; Tulic, M.K. Analysis of Matched Skin and Gut Microbiome of Patients with Vitiligo Reveals Deep Skin Dysbiosis: Link with Mitochondrial and Immune Changes. J. Investig. Dermatol. 2021, 141, 2280–2290.
  67. Conrad, C.; Gilliet, M. Type I IFNs at the Interface between Cutaneous Immunity and Epidermal Remodeling. J. Investig. Dermatol. 2012, 132, 1759–1762.
  68. Jacquemin, C.; Rambert, J.; Guillet, S.; Thiolat, D.; Boukhedouni, N.; Doutre, M.; Darrigade, A.; Ezzedine, K.; Blanco, P.; Taieb, A.; et al. Heat shock protein 70 potentiates interferon alpha production by plasmacytoid dendritic cells: Relevance for cutaneous lupus and vitiligo pathogenesis. Br. J. Dermatol. 2017, 177, 1367–1375.
  69. Singh, A.; Das, D.; Kurra, S.; Arava, S.; Gupta, S.; Sharma, A. Dendritic cells and their associated pro-inflammatory cytokines augment to the inflammatory milieu in vitiligo skin. Cytokine 2021, 148, 155598.
  70. Srivastava, N.; Bishnoi, A.; Parsad, D.; Kumaran, M.S.; Vinay, K.; Gupta, S. Dendritic cells sub-sets are associated with inflammatory cytokine production in progressive vitiligo disease. Obs. Study 2021, 313, 759–767.
  71. Bernardini, N.; Skroza, N.; Tolino, E.; Mambrin, A.; Anzalone, A.; Balduzzi, V.; Colapietra, D.; Marchesiello, A.; Michelini, S.; Proietti, I.; et al. IL-17 and its role in inflammatory, autoimmune, and oncological skin diseases: State of art. Int. J. Dermatol. 2020, 59, 406–411.
  72. Vivier, E.; Tomasello, E.; Baratin, M.; Walzer, T.; Ugolini, S. Functions of natural killer cells. Nat. Immunol. 2008, 9, 503–510.
  73. Basak, P.; Adiloglu, A.; Koc, I.; Taş, T.; Akkaya, V. Evaluation of activatory and inhibitory natural killer cell receptors in non-segmental vitiligo: A flow cytometric study. J. Eur. Acad. Dermatol. Venereol. 2008, 22, 970–976.
  74. Halder, R.M.; Walters, C.S.; Johnson, B.A.; Chakrabarti, S.G.; Kenney, J.A. Aberrations in T lymphocytes and natural killer cells in vitiligo: A flow cytometric study. J. Am. Acad. Dermatol. 1986, 14, 733–737.
  75. Regazzetti, C.; Joly, F.; Marty, C.; Rivier, M.; Mehul, B.; Reiniche, P.; Mounier, C.; Rival, Y.; Piwnica, D.; Cavalié, M.; et al. Transcriptional Analysis of Vitiligo Skin Reveals the Alteration of WNT Pathway: A Promising Target for Repigmenting Vitiligo Patients. J. Investig. Dermatol. 2015, 135, 3105–3114.
  76. Deng, Q.; Luo, Y.; Chang, C.; Wu, H.; Ding, Y.; Xiao, R. The Emerging Epigenetic Role of CD8+T Cells in Autoimmune Diseases: A Systematic Review. Front. Immunol. 2019, 10, 856.
  77. Lili, Y.; Yi, W.; Ji, Y.; Yue, S.; Weimin, S.; Ming, L. Global Activation of CD8+ Cytotoxic T Lymphocytes Correlates with an Impairment in Regulatory T Cells in Patients with Generalized Vitiligo. PLoS ONE 2012, 7, e37513.
  78. Yang, L.; Wei, Y.; Sun, Y.; Shi, W.; Yang, J.; Zhu, L.; Li, M. Interferon-gamma Inhibits Melanogenesis and Induces Apoptosis in Melanocytes: A Pivotal Role of CD8+ Cytotoxic T Lymphocytes in Vitiligo. Acta Derm. Venereol. 2015, 95, 664–670.
  79. Wańkowicz-Kalińska, A.; van den Wijngaard, R.M.J.G.J.; Tigges, B.J.; Westerhof, W.; Ogg, G.S.; Cerundolo, V.; Storkus, W.; Das, P.K. Immunopolarization of CD4+ and CD8+ T Cells to Type-1–Like is Associated with Melanocyte Loss in Human Vitiligo. Lab. Investig. 2003, 83, 683–695.
  80. Richmond, J.M.; Bangari, D.S.; Essien, K.I.; Currimbhoy, S.D.; Groom, J.R.; Pandya, A.G.; Youd, M.E.; Luster, A.D.; Harris, J.E. Keratinocyte-Derived Chemokines Orchestrate T-Cell Positioning in the Epidermis during Vitiligo and May Serve as Biomarkers of Disease. J. Investig. Dermatol. 2017, 137, 350–358.
  81. Bergqvist, C.; Ezzedine, K. Vitiligo: A focus on pathogenesis and its therapeutic implications. J. Dermatol. 2021, 48, 252–270.
  82. Benzekri, L.; Gauthier, Y. Clinical markers of vitiligo activity. J. Am. Acad. Dermatol. 2017, 76, 856–862.
  83. Maloy, K.; Powrie, F. Regulatory T cells in the control of immune pathology. Nat. Immunol. 2001, 2, 816–822.
  84. Giri, P.S.; Dwivedi, M.; Begum, R. Decreased suppression of CD8 + and CD4 + T cells by peripheral regulatory T cells in generalized vitiligo due to reduced NFATC1 and FOXP3 proteins. Exp. Dermatol. 2020, 29, 759–775.
  85. Giri, P.S.; Dwivedi, M.; Laddha, N.C.; Begum, R.; Bharti, A.H. Altered expression of nuclear factor of activated T cells, forkhead box P3, and immune-suppressive genes in regulatory T cells of generalized vitiligo patients. Pigment Cell Melanoma Res. 2020, 33, 566–578.
  86. ben Ahmed, M.; Zaraa, I.; Rekik, R.; Elbeldi-Ferchiou, A.; Kourda, N.; Belhadj Hmida, N.; Abdeladhim, M.; Karoui, O.; ben Osman, A.; Mokni, M.; et al. Functional defects of peripheral regulatory T lymphocytes in patients with progressive vitiligo. Pigment Cell Melanoma Res. 2012, 25, 9–109.
  87. Lin, M.; Zhang, B.-X.; Shen, N.; Dong, X.-J.; Zhang, C.; Mao-Qiang, M.; Zhu, J.; Li, Y.-Z.; Man, M.-Q.; Tu, C.-X. Regulatory T cells from active non-segmental vitiligo exhibit lower suppressive ability on CD8+CLA+ T cells. Eur. J. Dermatol. 2014, 24, 676–682.
  88. Klarquist, J.; Denman, C.J.; Hernandez, C.; Wainwright, D.; Strickland, F.M.; Overbeck, A.; Mehrotra, S.; Nishimura, M.I.; Le Poole, I.C. Reduced skin homing by functional Treg in vitiligo. Pigment Cell Melanoma Res. 2010, 23, 276–286.
  89. le Poole, I.C.; Mehrotra, S. Replenishing Regulatory T Cells to Halt Depigmentation in Vitiligo. J. Investig. Dermatol. Symp. Proc. 2017, 18, S38–S45.
  90. Eby, J.M.; Kang, H.-K.; Tully, S.T.; Bindeman, W.E.; Peiffer, D.S.; Chatterjee, S.; Mehrotra, S.; Le Poole, I.C. CCL22 to Activate Treg Migration and Suppress Depigmentation in Vitiligo. J. Investig. Dermatol. 2015, 135, 1574–1580.
  91. Dwivedi, M.; Kemp, E.H.; Laddha, N.C.; Mansuri, M.S.; Weetman, A.P.; Begum, R. Regulatory T cells in vitiligo: Implications for pathogenesis and therapeutics. Autoimmun. Rev. 2015, 14, 49–56.
  92. Clark, R.A. Resident memory T cells in human health and disease. Sci. Transl. Med. 2015, 7, 269rv1.
  93. Wakim, L.M.; Gebhardt, T.; Heath, W.; Carbone, F.R. Cutting Edge: Local Recall Responses by Memory T Cells Newly Recruited to Peripheral Nonlymphoid Tissues. J. Immunol. 2008, 181, 5837–5841.
  94. Ho, A.W.; Kupper, T.S. T cells and the skin: From protective immunity to inflammatory skin disorders. Nat. Rev. Immunol. 2019, 19, 490–502.
  95. Cheuk, S.; Schlums, H.; Sérézal, I.G.; Martini, E.; Chiang, S.C.; Marquardt, N.; Gibbs, A.; Detlofsson, E.; Introini, A.; Forkel, M.; et al. CD49a Expression Defines Tissue-Resident CD8+ T Cells Poised for Cytotoxic Function in Human Skin. Immunity 2017, 46, 287–300.
  96. Richmond, J.M.; Strassner, J.P.; Zapata, L., Jr.; Garg, M.; Riding, R.L.; Refat, M.A.; Fan, X.; Azzolino, V.; Tovar-Garza, A.; Tsurushita, N.; et al. Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo. Sci. Transl. Med. 2018, 10, eaam7710.
  97. Boniface, K.; Jacquemin, C.; Darrigade, A.-S.; Dessarthe, B.; Martins, C.; Boukhedouni, N.; Vernisse, C.; Grasseau, A.; Thiolat, D.; Rambert, J.; et al. Vitiligo Skin Is Imprinted with Resident Memory CD8 T Cells Expressing CXCR3. J. Investig. Dermatol. 2017, 138, 355–364.
  98. Frączek, A.; Owczarczyk-Saczonek, A.; Placek, W. The Role of TRM Cells in the Pathogenesis of Vitiligo—A Review of the Current State-Of-The-Art. Int. J. Mol. Sci. 2020, 21, 3552.
  99. Boniface, K.; Seneschal, J. Vitiligo as a skin memory disease: The need for early intervention with immunomodulating agents and a maintenance therapy to target resident memory T cells. Exp. Dermatol. 2019, 28, 656–661.
  100. Jacquemin, C.; Martins, C.; Lucchese, F.; Thiolat, D.; Taieb, A.; Seneschal, J.; Boniface, K. NKG2D Defines a Subset of Skin Effector Memory CD8 T Cells with Proinflammatory Functions in Vitiligo. J. Investig. Dermatol. 2019, 140, 1143–1153.e5.
  101. Martins, C.; Darrigade, A.; Jacquemin, C.; Barnetche, T.; Taieb, A.; Ezzedine, K.; Boniface, K.; Seneschal, J. Phenotype and function of circulating memory T cells in human vitiligo. Br. J. Dermatol. 2020, 183, 899–908.
  102. Zhang, J.; Yu, S.; Hu, W.; Wang, M.; Abudoureyimu, D.; Luo, D.; Li, T.; Long, L.; Zeng, H.; Cheng, C.; et al. Comprehensive Analysis of Cell Population Dynamics and Related Core Genes During Vitiligo Development. Front. Genet. 2021, 12, 627092.
  103. Willemsen, M.; Post, N.F.; van Uden, N.O.; Narayan, V.S.; Chielie, S.; Kemp, E.H.; Bekkenk, M.W.; Luiten, R.M. Immunophenotypic Analysis Reveals Differences in Circulating Immune Cells in the Peripheral Blood of Patients with Segmental and Nonsegmental Vitiligo. J. Investig. Dermatol. 2021, 142, 876–883.e3.
  104. Kemp, E.H.; Gavalas, N.G.; Gawkrodger, D.J.; Weetman, A.P. Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo. Autoimmun. Rev. 2007, 6, 138–142.
  105. Raam, L.; Kaleviste, E.; Šunina, M.; Vaher, H.; Saare, M.; Prans, E.; Pihlap, M.; Abram, K.; Karelson, M.; Peterson, P.; et al. Lymphoid Stress Surveillance Response Contributes to Vitiligo Pathogenesis. Front. Immunol. 2018, 9, 2707.
  106. Yang, L.; Yang, S.; Lei, J.; Hu, W.; Chen, R.; Lin, F.; Xu, A.-E. Role of chemokines and the corresponding receptors in vitiligo: A pilot study. J. Dermatol. 2018, 45, 31–38.
  107. Toussirot, É.; Aubin, F. Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: An analytical and comprehensive overview. RMD Open 2016, 2, e000239.
  108. Chen, X.; Guo, W.; Chang, Y.; Chen, J.; Kang, P.; Yi, X.; Cui, T.; Guo, S.; Xiao, Q.; Jian, Z.; et al. Oxidative stress-induced IL-15 trans-presentation in keratinocytes contributes to CD8+ T cells activation via JAK-STAT pathway in vitiligo. Free Radic. Biol. Med. 2019, 139, 80–91.
  109. Singh, R.K.; Lee, K.M.; Vujkovic-Cvijin, I.; Ucmak, D.; Farahnik, B.; Abrouk, M.; Nakamura, M.; Zhu, T.H.; Bhutani, T.; Wei, M.; et al. The role of IL-17 in vitiligo: A review. Autoimmun. Rev. 2016, 15, 397–404.
  110. Zhou, J.; An, X.; Dong, J.; Wang, Y.; Zhong, H.; Duan, L.; Ling, J.; Ping, F.; Shang, J. IL-17 induces cellular stress microenvironment of melanocytes to promote autophagic cell apoptosis in vitiligo. FASEB J. 2018, 32, 4899–4916.
  111. Sushama, S.; Dixit, N.; Gautam, R.K.; Arora, P.; Khurana, A.; Anubhuti, A. Cytokine profile (IL-2, IL-6, IL-17, IL-22, and TNF-α) in vitiligo—New insight into pathogenesis of disease. J. Cosmet. Dermatol. 2019, 18, 337–341.
  112. Speeckaert, R.; Mylle, S.; Van Geel, N. IL-17A is not a treatment target in progressive vitiligo. Pigment Cell Melanoma Res. 2019, 32, 842–847.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Dermatology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Nika Hlača
,
Tina Žagar
,
Marija Kaštelan
,
Ines Brajac
,
Larisa Prpić-Massari
View Times: 574
Revisions: 2 times (View History)
Update Date: 15 Jul 2022
Table of Contents
    1000/1000
    Hot Most Recent
    ScholarVision Creations
    Feedback